Welcome to our dedicated page for Atyr Pharma news (Ticker: ATYR), a resource for investors and traders seeking the latest updates and insights on Atyr Pharma stock.
aTyr Pharma, Inc. develops clinical-stage biotechnology programs based on its proprietary tRNA synthetase platform. Its news centers on efzofitimod, a biologic immunomodulator in development for interstitial lung disease, including pulmonary sarcoidosis and systemic sclerosis-related interstitial lung disease.
Company updates commonly cover EFZO-FIT and EFZO-CONNECT study activity, FDA interactions, quarterly and annual financial results, research and development spending, healthcare conference presentations, and equity award grants under Nasdaq inducement rules.
aTyr Pharma (Nasdaq: ATYR) updated the expected timing for U.S. FDA feedback on the protocol for its planned Phase 3 study of efzofitimod in chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease. Based on FDA feedback, the company anticipates a regulatory response by mid-September 2026.
The planned 54-week, global, randomized, double-blind, placebo-controlled trial is expected to enroll up to approximately 372 patients on stable low-dose corticosteroids and/or background immunosuppressants. Patients will receive either 5.0 mg/kg efzofitimod or placebo intravenously every three weeks. The primary endpoint is change from baseline in forced vital capacity at week 48, with a key secondary endpoint of change in King’s Sarcoidosis Questionnaire-Lung score at week 48.
aTyr Pharma (Nasdaq: ATYR) reported second quarter 2026 results and announced a major program prioritization and corporate restructuring to focus on its lead asset, efzofitimod, in interstitial lung disease (ILD), including pulmonary sarcoidosis and SSc‑ILD. The company is awaiting FDA feedback by the end of August 2026 on the protocol for a planned global Phase 3 pulmonary sarcoidosis trial and has completed enrollment in the Phase 2 EFZO‑CONNECT study in SSc‑ILD, with topline data expected in Q1 2027.
The restructuring includes a workforce reduction of about 60%, CFO and General Counsel transitions effective September 30, 2026, and is expected to cut annualized operating expenses by roughly $13 million from Q4 2026. aTyr ended the quarter with $58.9 million in cash, cash equivalents, restricted cash and investments and, according to the company, expects this to fund current operations into late 2028, though additional capital will be needed to conduct the planned Phase 3 study.
aTyr Pharma (Nasdaq: ATYR) reported a post hoc subgroup analysis from the Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis, focusing on 44 patients with prespecified restrictive lung disease (FVC percent predicted ≤ 80%, FEV1/FVC ≥ 0.7).
According to aTyr Pharma, patients receiving 5.0 mg/kg efzofitimod showed a placebo-adjusted week 48 change from baseline in FVC of 123.8 ml using a random coefficient regression model, along with improvements across multiple patient-reported outcomes including KSQ-Lung, KSQ-General Health, Fatigue Assessment Scale and Leicester Cough Questionnaire. Steroid reduction in this dose arm was similar to placebo, and efzofitimod was generally well tolerated. In June 2026, the company submitted to the FDA a protocol for a planned Phase 3 study in chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease, using FVC as the primary endpoint and KSQ-Lung as the key secondary endpoint.
aTyr Pharma (Nasdaq: ATYR) reported first quarter 2026 results and a corporate update. The company ended March 31, 2026 with $68.3 million in cash, cash equivalents, restricted cash and investments.
aTyr will continue developing efzofitimod in pulmonary sarcoidosis, plans a new global Phase 3 trial after an FDA Type C meeting, and remains on track to complete enrollment in the Phase 2 EFZO-CONNECT SSc-ILD study in the first half of 2026.
aTyr Pharma (Nasdaq: ATYR) will participate in two investor conferences in New York in May and June 2026. Events include the RBC Capital Markets Global Healthcare Conference on May 20 with 1x1 meetings and the Jefferies Global Healthcare Conference on June 4 featuring a fireside chat.
A webcast and 90-day replay of the Jefferies presentation will be available on aTyr’s investor relations website.
aTyr Pharma (Nasdaq: ATYR) outlined its regulatory and clinical path for efzofitimod in pulmonary sarcoidosis after an FDA Type C meeting.
The company plans to submit an IND in June 2026 for a new global Phase 3 trial using FVC as the primary endpoint and KSQ-Lung as a key secondary endpoint in patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease.
The 54-week, randomized, double-blind, placebo-controlled study is expected to enroll up to approximately 372 patients, with dosing every three weeks and stable background corticosteroid and/or immunosuppressant therapy.
aTyr Pharma (Nasdaq: ATYR) reported full-year 2025 results and a corporate update. The company ended 2025 with $80.9 million in cash, cash equivalents, restricted cash and investments. R&D expense was $60.2 million and G&A expense was $17.6 million.
The Phase 3 EFZO-FIT study in pulmonary sarcoidosis did not meet its primary endpoint, but 5.0 mg/kg efzofitimod showed clinical benefit on multiple secondary measures. A Type C meeting with the FDA is scheduled for mid-April 2026.
aTyr Pharma (Nasdaq: ATYR) disclosed inducement option grants dated February 17, 2026, awarding two new employees an aggregate of 12,200 nonstatutory stock options at an exercise price of $0.98 per share, equal to the closing price on that date.
Each option vests over four years (25% at one year, then monthly over three years) and was granted under the 2022 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
aTyr Pharma (Nasdaq: ATYR) will present at the Leerink Partners Global Healthcare Conference in Miami on March 11, 2026 at 8:00 AM EDT. President and CEO Sanjay S. Shukla, M.D., M.S. will deliver a corporate presentation and meet one-on-one with registered investors.
A live webcast will be available on the company’s Investor section and a replay will remain on the aTyr website for at least 90 days.
aTyr Pharma (Nasdaq: ATYR) said the FDA accepted a Type C meeting request to discuss efzofitimod for pulmonary sarcoidosis, scheduled for mid-April 2026. The company will review Phase 3 EFZO-FIT results and report meeting minutes afterwards.
The Phase 3 study enrolled 268 patients; it did not meet the primary endpoint of corticosteroid dose reduction at week 48, but 5.0 mg/kg efzofitimod showed statistically significant benefits on multiple patient-reported outcomes and maintained lung function, with a safety profile consistent with prior trials.